Dollar Hits Strongest Level in Five Weeks Ahead of Key US Data
The Bloomberg Dollar Spot Index advanced 0.3% to the highest level since June 23 as the greenback rose against all its Group-of-10 peers. European currencies led losses, with the euro extending its slide to the weakest level in more than a month amid concern over the economic impact of the EU's recent trade deal with the US.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a few seconds ago
- Yahoo
Australia Anti-Venom Market Analysis Report 2025-2033 Featuring BSV, Boehringer Ingelheim, Boston Scientific, CSL, Merck, Pfizer, Haffkine Bio-Pharmaceutical
The Australia Anti Venom Market is poised for significant growth, reaching an estimated US$ 39.27 million by 2033 from US$ 22.18 million in 2024, at a CAGR of 6.55% from 2025 to 2033. This expansion is driven by increasing snake and scorpion bites, government initiatives, and industry advancements. Key market segments include Polyvalent and Monovalent Anti-Venoms, targeting snakes, scorpions, and spiders, distributed through clinics, hospitals, and surgical centers. Despite challenges like high production costs and geographic logistics, ongoing research and community engagement aim to enhance antivenom efficacy and accessibility. Major companies include CSL Limited and Pfizer Inc. Australian Anti-Venom Market Dublin, July 30, 2025 (GLOBE NEWSWIRE) -- The "Australia Anti-Venom Market - Healthcare Demand & Forecast 2025-2033" report has been added to Anti Venom Market is expected to reach US$ 39.27 million by 2033 from US$ 22.18 million in 2024, with a CAGR of 6.55% from 2025 to 2033. Increasing rates of snake bites and scorpion stings, the introduction of beneficial government programs, and continuous industry advancements are some of the major factors propelling the market's expansion. The anti-venom business in Australia is essential to safeguarding the general public's health from the deadly and varied animals of the nation. The need for efficient anti-venom therapies is constantly high in areas with a high population of poisonous snakes and spiders. The industry functions through a network of organizations in charge of producing anti-venom, conducting research, and extracting venom. Together, these groups strive to guarantee a consistent flow of therapies that can save lives throughout the order to create anti-venom, venom from animals is usually collected and used to immunize host animals, such horses. The anti-venom is then made by harvesting and purifying antibodies. Although this approach hasn't altered much in decades, it still works well. The sector still confronts obstacles despite its shown success, such as high production costs and the requirement for anti-venoms that are appropriate for certain venom kinds. To overcome these obstacles and enhance results, research and innovation are still being conducted. Researchers are looking at universal anti-venoms that can cure various venom kinds as well as more effective manufacturing methods. Additionally, efforts are being made to make treatments more widely available, particularly in rural and isolated locations where bites are more common. In order to maintain national safety as the business develops, its capacity to address public health demands continues to be a top Factors Driving the Australia Anti Venom Market Growth High Incidence of Venomous BitesSome of the deadliest snakes and spiders in the world, such as the eastern brown snake, funnel-web spider, and inland taipan, may be found in Australia. A steady number of envenomation cases occur annually as a result of the widespread presence of these harmful species across the nation. The ongoing need for efficient anti-venom remedies is fueled by this public health concern. Particularly in rural and isolated areas where interactions are more frequent, hospitals and emergency services need to keep enough supplies on hand to react promptly to bites. Continued investment in the development and dissemination of anti-venoms is guaranteed by the necessity to treat both common and uncommon venom exposures. The need for dependable, quick-acting medical treatments like anti-venom therapy is growing as people become more aware of the dangers posed by local in Research and DevelopmentThe Australian anti-venom business is expanding due in large part to ongoing research and innovation. The goal of scientific research is to improve the accessibility, efficacy, and safety of therapies. The search for universal anti-venoms that can cure bites from many species is a significant area of development that might expedite emergency response and lower expenses. In order to boost productivity and lessen dependency on conventional animal-based vaccination, researchers are also trying to improve production techniques through the use of cutting-edge biotechnology. Collaboration among government organizations, pharmaceutical businesses, and academic institutions facilitates the creation of regionally customized solutions that are suited to Australia's distinct ecology. These developments guarantee that anti-venoms will continue to effectively combat changing venom characteristics and effectively and safely address public health Engagement and Public AwarenessIn Australia, the anti-venom business is greatly aided by community engagement. To properly catch and milk poisonous creatures, programs like wildlife parks' venom collecting campaigns need on volunteers and skilled specialists. In order to create medicines that can save lives, this gathered venom is essential. Public education initiatives also assist lower the number of fatalities and problems by increasing knowledge about the safety of snakes and spiders, first aid procedures, and the value of prompt medical attention. Raising awareness also promotes public and private funding for the study and manufacture of anti-venom. Australia guarantees a more proactive and robust approach to addressing the hazards posed by venomous animals by cultivating a culture of shared responsibility among scientists, healthcare professionals, and the general in the Australia Anti Venom Market High Production CostsThe high cost of manufacture is one of the main issues facing the Australian anti-venom business. The production of anti-venoms usually entails a time-consuming procedure that includes venom vaccination of animals (like horses) followed by the collection and purification of the antibodies. Manufacturing costs are increased by this labor-intensive and intricate process, which calls for specialized facilities and knowledgeable workers. Additionally, keeping a steady supply of venom from a variety of species raises the operational and logistical expenses. These costs can restrict access and frequently result in significant costs for healthcare providers, especially in rural or resource-poor locations where envenomation cases are more and Logistical ChallengesThe dissemination of anti-venoms is severely hampered by Australia's large and sometimes rural terrain. A large number of envenomation cases take place in isolated and rural areas with little access to healthcare services. It can be challenging to get temperature-sensitive anti-venoms to these locations in a timely and reliable manner, particularly in the event of severe weather or infrastructural failures. Coordinated logistics and significant money are needed to guarantee that remote clinics and hospitals have enough inventory. In these areas, inadequate access might cause treatment delays and worsen health outcomes. Improving response times and guaranteeing that all Australians, wherever they may be, have access to life-saving anti-venoms depend on resolving these logistical concerns. Company Analysis: Overview, Key Persons, Recent Developments, Revenue Analysis Bharat Serums and Vaccines Limited (BSV) Boehringer Ingelheim International GmbH Boston Scientific Corporation CSL Limited. Merck KGaA Pfizer Inc. Haffkine Bio-Pharmaceutical Corporation Limited Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $22.18 Million Forecasted Market Value (USD) by 2033 $39.27 Million Compound Annual Growth Rate 6.5% Regions Covered Australia Key Topics Covered: 1. Introduction2. Research & Methodology2.1 Data Source2.1.1 Primary Sources2.1.2 Secondary Sources2.2 Research Approach2.2.1 Top-Down Approach2.2.2 Bottom-Up Approach2.3 Forecast Projection Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. Australia Anti Venom Market5.1 Historical Market Trends5.2 Market Forecast6. Market Share Analysis6.1 By Type6.2 By Animal Type6.3 By End Users7. Type7.1 Polyvalent Anti-Venom7.2 Monovalent Anti-Venom8. Animal Type8.1 Snake8.2 Scorpion8.3 Spider8.4 Others9. End Users9.1 Clinics9.2 Hospitals9.3 Ambulatory Surgical Centers9.4 Others10. Porter's Five Forces Analysis10.1 Bargaining Power of Buyers10.2 Bargaining Power of Suppliers10.3 Degree of Rivalry10.4 Threat of New Entrants10.5 Threat of Substitutes11. SWOT Analysis11.1 Strength11.2 Weakness11.3 Opportunity11.4 Threat12. Key Players Analysis For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Australian Anti-Venom Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
3 minutes ago
- Business Upturn
Welspun Living Q1 Results: Revenue falls 11.6% YoY to Rs 2,289 crore, net profit down 52.8% YoY
By Aman Shukla Published on July 30, 2025, 15:12 IST Welspun Living Ltd reported its financial results for the first quarter of FY26, showing a dip in consolidated revenue to ₹2,289 crore, down 11.6% year-on-year. EBITDA stood at ₹254 crore, reflecting a decline of 35.4% from the same period last year. The EBITDA margin also contracted to 11.1%, compared to 15.2% in Q1FY25. Profit after tax dropped sharply by 52.8% YoY to ₹88 crore. The company's Home Textile segment, its core revenue contributor, saw a 11.1% drop in revenue to ₹2,123 crore. EBITDA for the segment came in at ₹223 crore, with a margin of 10.5%. The Flooring segment revenue fell 15.1% YoY to ₹194 crore, with EBITDA at ₹16 crore. Despite the overall decline, Welspun's domestic consumer business grew 9.5% YoY. The company also reported progress on its financial discipline, with net debt reduced to ₹1,401 crore and an improved cash conversion cycle of 88 days. In a strategic move, the Board has approved an investment of US$13 million to set up a Pillow and TOB (Top of Bed) facility in Nevada, USA, strengthening its global manufacturing footprint. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Bloomberg
3 minutes ago
- Bloomberg
S&P 500's Banner Rally Faces Off With Worst Two Months of Year
The S&P 500 Index, coming off its best streak of gains since 2020, is about to enter what has historically been its toughest stretch of the year. Over the past three decades, the benchmark has performed the worst in August and September, losing 0.7% on average in each month, compared with a 1.1% gain on average across other months, data compiled by Bloomberg show. Analysts attribute the pattern in part to money managers' tendency to reassess their portfolios around this time of year.
